Company Filing History:
Years Active: 2012-2016
Title: Ulrich Zanger: Innovator in Pharmacogenomics
Introduction
Ulrich Zanger is a notable inventor based in Korntal, Germany. He has made significant contributions to the field of pharmacogenomics, particularly in understanding how genetic variations affect drug metabolism and response. With a total of 2 patents, Zanger's work has implications for personalized medicine and improving patient outcomes.
Latest Patents
Zanger's latest patents include a method for determining the predisposition of a patient to changed biotransformation and the development of undesired drug effects in treatment with atorvastatin. This method involves identifying single nucleotide polymorphisms (SNPs) in the UGT1A3 gene and assessing gene expression in biological samples. His second patent focuses on polymorphisms in the human CYP2D6 gene promoter region, which are associated with abnormal drug responses. This patent provides polynucleotides for diagnosing drug metabolism status and includes diagnostic kits for identifying patients who are ultrarapid or intermediate metabolizers.
Career Highlights
Throughout his career, Zanger has worked with prominent companies such as Robert Bosch GmbH and Pgxhealth, LLC. His expertise in pharmacogenomics has positioned him as a key figure in the development of diagnostic tools that enhance the understanding of drug interactions and patient-specific treatment plans.
Collaborations
Zanger has collaborated with notable colleagues, including Kathrin Klein and Stephan Riedmaier. These partnerships have furthered research in the field and contributed to advancements in personalized medicine.
Conclusion
Ulrich Zanger's innovative work in pharmacogenomics highlights the importance of genetic factors in drug therapy. His patents and collaborations reflect a commitment to improving healthcare through personalized approaches.